1.原文連結：
https://reurl.cc/v1xZGN
2.原文內容：
AstraZeneca/Oxford vaccine shows 'strong immune response' in all ages
Early results from the latest stage of testing for AstraZeneca (AZN.L) and
the University of Oxford’s possible COVID-19 vaccine show a “strong immune
response... across all age groups.”
AstraZeneca on Thursday said interim results from its Phase II/III trial
showed patients given the vaccine exhibited a “robust immune response.”
Crucially, participants of all ages showed an immune system reaction.
“It is essential that a COVID-19 vaccine can be effective across a broad age
range, particularly in older individuals where they are disproportionately at
risk of severe COVID-19 disease,” said Mene Pangalos, executive vice
president of BioPharmaceuticals R&D at AstraZeneca.
Almost 13,000 people in the UK are taking part in the trial of the vaccine
and 60,000 people around the world are trialling it. The vaccine candidate is
being developed in partnership with the University of Oxford.
Patients who received the vaccine experienced some “mild, local and systemic
reactions,” such as pain in the injection site and headaches. Older patients
who received the vaccine showed less symptoms than young participants.
Professor Andrew Pollard, the head of Oxford’s vaccine trial team, told BBC
Radio 4’s Today programme: “Adults tend to feel a bit ropey the day after
they have been vaccinated.”
AstraZeneca said it was inconclusive whether the vaccine generated a lasting
immunity to COVID-19 for patients who receive it.
UK health secretary Matt Hancock said the results were a “really encouraging
set of findings.” Earlier this year Britain signed a deal to buy 100 million
doses of the AstraZeneca and University of Oxford vaccine if successful.
Dr Michael Tildesley, who sits on a Sage sub-group, told BBC Breakfast the
vaccine could “hopefully [be] one of the key game changers.”
Professor Pollard told the Today programme he was “absolutely delighted”
with the interim results.
Shares in AstraZeneca rose over 1% at the open in London.
The results add to the recent mood of optimism around hopes for a COVID-19
vaccine that could end the pandemic.
Last week Pfizer (PFE) and BioNTech (BNTX) announced their vaccine candidate
was 90% effective in trials. They followed with a further update yesterday
saying final analysis suggested it was in fact 95% effective.
This week US biotech company Moderna (MRNA) said its vaccine was 94.5%
effective in trials.
“Overall the newsflow has been incredibly positive in the last couple of
weeks,” said Jim Reid, a senior investment strategist at Deutsche Bank.
3.心得/評論：
又一個疫苗的好消息，不過看來現在這種消息已經影響不了市場了
AstraZeneca 的股價今天也沒什麼動